News & Updates

Adding the investigational selective prostacyclin receptor agonist ralinepag to background therapy helps reduce the risk of first clinical worsening in patients with pulmonary arterial hypertension (PAH), according to the phase III ADVANCE-OUTCOMES trial.

A 5-day treatment course with nirmatrelvir–ritonavir appears to extend its benefit past the acute infection period, having been linked to reduced long COVID risk in the randomized controlled PANORAMIC Norway trial.

Cigarette smoking and use of heated tobacco products (HTPs) are both linked to lower physical activity in Japanese adults, especially those with respiratory diseases, according to a study.

Patients with pulmonary arterial hypertension treated with sotatercept demonstrate improved exercise tolerance, driven in part by increased haemoglobin, according to a study.

Residual perfusion defects normally persist following acute pulmonary embolism, indicating a more severe initial disease phenotype, according to a study.